|Mr. Ilan Ganot||Co-founder, Pres, CEO & Director||713.05k||N/A||1974|
|Mr. Matthew Bennett Arnold||Co-Founder & Independent Director||42.5k||N/A||1970|
|Ms. Annie Ganot||Co-Founder & Director of Patient Advocacy||N/A||N/A||N/A|
|Ms. Jennifer Ziolkowski CPA, CPA||CFO & Treasurer||N/A||N/A||1974|
|Dr. Joel Solomon Zev Schneider||Chief Technology Officer||N/A||N/A||1985|
|Dr. Carl Ashley Morris||Chief Scientific Officer||N/A||N/A||1970|
|Mr. Geoffrey M. Grande||VP & Head of Investor Relations||N/A||N/A||N/A|
|Ms. Lynette A. Herscha J.D.||Chief Legal Officer & Sec.||N/A||N/A||1972|
|Dr. Cathryn M. Clary M.B.A., M.D.||Acting Chief Medical Officer||N/A||N/A||N/A|
Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to derive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Solid Biosciences Inc.’s ISS Governance QualityScore as of December 1, 2020 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 8; Compensation: 7.